Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Public ClinicalTrials.gov record NCT02608099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the prospective, randomized cohort in this study is to assess the safety and efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation (NVAF). Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by chart review, who are matched to the prospective randomized subjects, will be identified. The purpose of the retrospective warfarin cohort is to compare the efficacy and safety of warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted, combined uninterrupted and interrupted).
Study identification
- NCT ID
- NCT02608099
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2015 (Type not available)
- Primary completion
- Apr 2017 (Actual)
- Completion
- Apr 2017 (Actual)
- Last update posted
- Mar 17, 2020
2015 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 0020 | Huntsville | Alabama | 35801 | — |
| Site 0005 | Mission Viejo | California | 92690 | — |
| Site 0012 | New Haven | Connecticut | 06501 | — |
| Site 0011 | Trumbull | Connecticut | 06611 | — |
| Site 0016 | Pensacola | Florida | 32501 | — |
| Site 0014 | West Des Moines | Iowa | 50266 | — |
| Site 0018 | Bangor | Maine | 04401 | — |
| Site 0004 | Scarborough | Maine | 04074 | — |
| Site 0008 | Boston | Massachusetts | 02118 | — |
| Site 0001 | Burlington | Massachusetts | 01805 | — |
| Site 0006 | Kansas City | Missouri | 64111 | — |
| Site 0021 | Omaha | Nebraska | 68131 | — |
| Site 0019 | Albuquerque | New Mexico | 87101 | — |
| Site 0002 | Toledo | Ohio | 43615 | — |
| Site 0007 | Oklahoma City | Oklahoma | 73104 | — |
| Site 0009 | Philadelphia | Pennsylvania | 19019 | — |
| Site 0010 | Charleston | South Carolina | 29401 | — |
| Site 0017 | Austin | Texas | 78705 | — |
| Site 0003 | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02608099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2020 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02608099 live on ClinicalTrials.gov.